Mark Chao, TenSixteen CEO

With Forty Sev­en co-founder at the helm, new biotech spin­out launch­es to tar­get mu­ta­tions po­ten­tial­ly linked to nu­mer­ous dis­eases

Mark Chao is go­ing back in­to biotech — and his new com­pa­ny, launched this morn­ing, is go­ing af­ter mys­te­ri­ous mu­ta­tions in the blood and how they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.